Product Reports Resources Pricing Login Book a demo

Celltrion

Biotech & Life Sciences · Incheon, South Korea · Founded 2002 · IPO 2005

Global biotech company that launched the world's first monoclonal antibody biosimilar

Valuation $38B
Revenue $4.57B
EBITDA $1.29B

Talent graph

Celltrion's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Celltrion's cap table

Sourced from Dealroom's funding and investor records.

Series A 2 investors entered at this stage
KT&G Corporation
VaxGen

Global footprint

Where Celltrion has talent and traffic

Workforce by country
🇰🇷 South Korea · Incheon HQ
Book a demo for the full country breakdown
Web traffic by country
94K monthly visits
across markets
🏳️ Korea85.5%
🏳️ Republic of4.5%
🇺🇸 United States2.2%
🇵🇭 Philippines2%
🇬🇧 United Kingdom1.6%
Top 5 markets shown

Patent intelligence

$107M patent portfolio · 171 active families

Estimated portfolio value
$107M
0.28% of market cap · 4.6× smaller than top peer Genmab ($488M)
171 active patent families
Where Celltrion innovates Antiendomysial antibodiesBiochemistryBioinformaticsChemistryCoronavirus

Where Celltrion concentrates vs peers

Each axis is a top-10 topic across Celltrion and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Celltrion's 4 investments and acquisitions.

Every disclosed deal where Celltrion appeared as a backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Celltrion's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Celltrion deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Celltrion's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Celltrion

        An AI-synthesized read of the highest-engagement posts about Celltrion on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Celltrion on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.